EMA/306201/2013

European Medicines Agency decision

P/0147/2013

of 3 July 2013

on the agreement of a paediatric investigation plan and on the granting of a waiver for metformin (hydrochloride) (EMEA-001352-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0147/2013

of 3 July 2013

on the agreement of a paediatric investigation plan and on the granting of a waiver for metformin (hydrochloride) (EMEA-001352-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by EffRx Pharmaceuticals SA on 6 August 2012 under Article 15(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 17 May 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for metformin (hydrochloride), effervescent tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for metformin (hydrochloride), effervescent tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together appendices, is hereby granted.

Article 3

This decision is addressed to EffRx Pharmaceuticals SA, Wolleraustrasse 41 B, 8807 – Freienbach, Switzerland.

Done at London, 3 July 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/123607/2013

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMEA-001352-PIP01-12

Scope of the application

Active substance(s):

Metformin (hydrochloride)

Condition(s):

Treatment of polycystic ovary syndrome

Pharmaceutical form(s):

Effervescent tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

EffRx Pharmaceuticals SA

Basis for opinion

Pursuant to Article 15 of Regulation (EC) No 1901/2006 as amended, EffRx Pharmaceuticals SA submitted for agreement to the European Medicines Agency on 6 August 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 12 September 2012.

Supplementary information was provided by the applicant on 22 February 2013.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population and Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 17 May 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of polycystic ovary syndrome

The waiver applies to:

- Boys from birth to less than 18 years and premenarcheal girls;
- for effervescent tablets, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

And to:

- Postmenarcheal girls less than 2 years post-menarche or below 14 years of age for girls with primary amenorrhea;
- for effervescent tablets, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subsets.

2. Paediatric Investigation Plan

2.1. Condition: treatment of polycystic ovary syndrome

2.1.1. Indication(s) targeted by the PIP

Treatment of polycystic ovary syndrome as adjunct to diet and exercise in adolescent girls to improve menstrual regularity and insulin resistance.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

Girls from 2 years post-menarche or from 14 years of age for patients with primary amenorrhea to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Effervescent tablets.

2.1.4. Measures

Area	Number of measures	Description
Quality	1	**Measure 1:** Development of new pharmaceutical form for use in the paediatric population: effervescent tablet for oral use.
Non-clinical	0	Not applicable.

Area	Number of measures	Description
Clinical	2	**Measure 2:** Population based pharmacokinetic modelling and simulation approach of metformin PK data from published data in adults and adolescents to girls from 2 years post-menarche to less than 18 years of age with Polycystic Ovary Syndrome. **Measure 3:** Randomized, double-blind, placebo-controlled trial to determine the safety and efficacy of metformin on improvement of menstruation cycle regularity in adolescent girls from 2 years post-menarche to less than 18 years of age with Polycystic Ovary Syndrome.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By May 2016.
Deferral for one or more measures contained in the paediatric investigation plan:	No